Recent advances in the management of choreas

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 2, 2013, Pages 117-127

  Burgunder, Jean Marc ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chorea; diagnosis; Huntington's disease; management; treatment

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CONTRACEPTIVE AGENT; DIMEBON; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; NABILONE; NEUROLEPTIC AGENT; OLANZAPINE; PENICILLAMINE; PSYCHOSTIMULANT AGENT; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TIAPRIDE; ZINC DERIVATIVE;

ANAMNESIS; CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

EID: 84874451388     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612471700     Document Type: Review

References (66)

1. Almqvist E. Bloch M. Brinkman R. Craufurd D. Hayden M. (1999) A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 64: 1293–1304.
2. Almqvist E. Brinkman R. Wiggins S. Hayden M. (2003) Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin Genet 64: 300–309.
3. Anderson K. Craufurd D. Edmondson M. Goodman N. Groves M. van Duijn E. et al. (2011) An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's disease. PLoS Curr 3: RRN1261.
4. Appl T. Kaltenbach L. Lo D. Terstappen G. (2012) Targeting mutant huntingtin for the development of disease-modifying therapy. Drug Discov Today 17: 1217–1223.
5. Armstrong M. Miyasaki J. (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79: 597–603.
6. Bachoud-Levi A. Gaura V. Brugieres P. Lefaucheur J. Boisse M. Maison P. et al. (2006) Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 5: 303–309.
7. Bauer P. Kreuz F. Burk K. Saft C. Andrich J. Heilemann H. et al. (2006) Mutations in TITF 1 are not relevant to sporadic and familial chorea of unknown cause. Mov Disord 21: 1734–1737.
8. Bohlen S. Ekwall C. Hellstrom K. Vesterlin H. Bjornefur M. Wiklund L. et al. (2012) Physical therapy in Huntington's disease - toward objective assessments? Eur J Neurol, in press.
9. Bonelli R. Hofmann P. (2007) A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 8: 141–153.
10. Bonelli R. Wenning G. (2006) Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 12: 2701–2720.
11. Bronstein J. Tagliati M. Alterman R. Lozano A. Volkmann J. Stefani A. et al. (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68: 165.
12. Burgunder J. Gasser T. Harbo H. Finsterer J. (2010) Overview of the New European Federation of Neurological Societies’ Guidelines on Molecular Diagnosis of Neurological Disorders. Eur Neurol Rev 5: 12–17.
13. Burgunder J. Guttman M. Perlman S. Goodman N. van Kammen D. Goodman L. (2011) An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr 3: RRN1260.
14. Cardoso F. Seppi K. Mair K. Wenning G. Poewe W. (2006) Seminar on choreas. Lancet Neurol 5: 589–602.
15. Chen W. Lin Y. Xiong Z. Wei W. Ni W. Tan G. et al. (2011) Exome sequencing identifies truncating mutations in PRRT 2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet 43: 1252–1255.
16. Cicchetti F. Saporta S. Hauser R. Parent M. Saint-Pierre M. Sanberg P. et al. (2009) Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 106: 12483–12488.
17. Connick P. Kolappan M. Patani R. Scott M. Crawley C. He X. et al. (2011) The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 12: 62.
18. Curtis A. Mitchell I. Patel S. Ives N. Rickards H. (2009) A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 24: 2254–2259.
19. Edwards T. Zrinzo L. Limousin P. Foltynie T. (2012) Deep brain stimulation in the treatment of chorea. Mov Disord 27: 357–363.
20. Frank S. Ondo W. Fahn S. Hunter C. Oakes D. Plumb S. et al. (2008) A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 31: 127–133.
21. Giralt A. Friedman H. Caneda-Ferron B. Urban N. Moreno E. Rubio N. et al. (2010) BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther 17: 1294–1308.
22. Gras D. Jonard L. Roze E. Chantot-Bastaraud S. Koht J. Motte J. et al. (2012) Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry 83: 956–962.
23. Groves M. van Duijn E. Anderson K. Craufurd D. Edmondson M. Goodman N. et al. (2011) An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr 3: RRN1259.
24. Harbo H. Finsterer J. Baets J. van Broeckhoven C. Di Donato S. Fontaine B. et al. (2009) EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol 16: 777–785.
25. HORIZON Investigators of the Huntington Disease Study Group and European Huntington's Disease Network (2012) A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. Arch Neurol, in press.
26. Hoth K. Paulsen J. Moser D. Tranel D. Clark L. Bechara A. (2007) Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 29: 365–376.
27. HSG (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11: 136–142.
28. HSG (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366–372.
29. Jung H. Danek A. Walker R. (2011) Neuroacanthocytosis syndromes. Orphanet J Rare Dis 6: 68.
30. Krauss J. Loher T. Weigel R. Capelle H. Weber S. Burgunder J. (2003) Chronic stimulation of the globus pallidus internus for treatment of non-dYT1 generalized dystonia and choreoathetosis: 2-year follow up. J Neurosurg 98: 785–792.
31. Krauss J. Pohle T. Weber S. Ozdoba C. Burgunder J. (1999) Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet 354: 837–838.
32. Landwehrmeyer G. Dubois B. de Yebenes J. Kremer B. Gaus W. Kraus P. et al. (2007) Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 62: 262–272.
33. Lefaucheur R. Guyant-Marechal L. Wallon D. Nicolas G. Borden A. Maltete D. et al. (2012) Chorea in an 83-year-old woman: don't forget Huntington's disease. J Am Geriatr Soc 60: 983–984.
34. Li P. Huang R. Song W. Ji J. Burgunder J. Wang X. et al. (2012) Deep brain stimulation of the globus pallidus internal improves symptoms of chorea-acanthocytosis. Neurol Sci 33: 269–274.
35. Loher T. Krauss J. Wielepp J. Weber S. Burgunder J. (2002) Pallidal deep brain stimulation in a parkinsonian patient with late-life dementia: sustained benefit in motor symptoms but not in functional disability. Eur Neurol 47: 122–123.
36. Losekoot M. van Belzen M. Seneca S. Bauer P. Stenhouse S. Barton D. (2012) EMQN / CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet, in press.
37. Macleod R. Tibben A. Frontali M. Evers-Kiebooms G. Jones A. Martinez-Descales A. et al. (2012) Recommendations for the predictive genetic test in Huntington's disease. Clin Genet, in press.
38. Margolis R. Holmes S. Rosenblatt A. Gourley L. O'Hearn E. Ross C. et al. (2004) Huntington's disease-like 2 (HDL2) in North America and Japan. Ann Neurol 56: 670–674.
39. Marks S. Hung S. Rosielle D. (2011) Palliative care for patients with Huntington's disease #201. J Palliat Med 14: 655–656.
40. Martino D. Stamelou M. Bhatia K. (2012) The differential diagnosis of Huntington's disease-like syndromes: ‘red flags’ for the clinician. J Neurol Neurosurg Psychiatry, in press.
41. Mestre T. Ferreira J. Coelho M. Rosa M. Sampaio C. (2009 a) Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 3: CD006455.
42. Mestre T. Ferreira J. Coelho M. Rosa M. Sampaio C. (2009 b) Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 3: CD006456.
43. Nance M. (2012) Therapy in Huntington's disease: where are we? Curr Neurol Neurosci Rep 12: 359–366.
44. Nicolas G. Devys D. Goldenberg A. Maltete D. Herve C. Hannequin D. et al. (2011) Juvenile Huntington disease in an 18-month-old boy revealed by global developmental delay and reduced cerebellar volume. Am J Med Genet A 155A: 815–818.
45. Poon L. Kang G. Lee A. (2010) Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother 44: 1080–1089.
46. Prashanth L. Fox S. Meissner W. (2011) l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol 98: 31–54.
47. Quinn L. Busse M. (2012 a) Development of physiotherapy guidance and treatment-based classifications for people with Huntington's disease. Neurodegen Dis Manage 2: 11–19.
48. Quinn L. Busse M. (2012 b) Physiotherapy clinical guidelines for Huntington's disease. Neurodegen Dis Manage 2: 21–31.
49. Quinn N. Brown R. Craufurd D. Goldman S. Hodges J. Kieburtz K. et al. (1996) Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov Disord 11: 143–150.
50. Ribai P. Nguyen K. Hahn-Barma V. Gourfinkel-An I. Vidailhet M. Legout A. et al. (2007) Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 patients. Arch Neurol 64: 813–819.
51. Rosencrantz R. Schilsky M. (2011) Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis 31: 245–259.
52. Saft C. Lauter T. Kraus P. Przuntek H. Andrich J. (2006) Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. BMC Neurol 6: 11.
53. Schneider S. van de Warrenburg B. Hughes T. Davis M. Sweeney M. Wood N. et al. (2006) Phenotypic homogeneity of the Huntington disease-like presentation in a SCA 17 family. Neurology 67: 1701–1703.
54. Snowden J. Craufurd D. Griffiths H. Neary D. (1998) Awareness of involuntary movements in Huntington disease. Arch Neurol 55: 801–805.
55. t'Hart E. Marinus H. Burgunder J. Bentivoglio A. Craufurd D. Reilmann R. et al. (2012) Better global and cognitive functioning for choreatic versus hypokinetic-rigid Huntington's disease. J Neurol Neurosurg Psych 83(Suppl. 1): A36.
56. Tabrizi S. Langbehn D. Leavitt B. Roos R. Durr A. Craufurd D. et al. (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8: 791–801.
57. Tabrizi S. Reilmann R. Roos R. Durr A. Leavitt B. Owen G. et al. (2012) Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11: 42–53.
58. Tabrizi S. Scahill R. Durr A. Roos R. Leavitt B. Jones R. et al. (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10: 31–42.
59. Takami T. Terai S. Sakaida I. (2012) Advanced therapies using autologous bone marrow cells for chronic liver disease. Discov Med 14 (74): 7–12.
60. Tibben A. (2007) Predictive testing for Huntington's disease. Brain Res Bull 72: 165–171.
61. Tomita H. Nagamitsu S. Wakui K. Fukushima Y. Yamada K. Sadamatsu M. et al. (1999) Paroxysmal kinesigenic choreoathetosis locus maps to chromosome 16p11.2-q12.1. Am J Hum Genet 65: 1688–1697.
62. Venuto C. McGarry A. Ma Q. Kieburtz K. (2012) Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 27: 31–41.
63. Volkmann J. Allert N. Voges J. Sturm V. Schnitzler A. Freund H. (2004) Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol 55: 871–875.
64. Wardle M. Morris H. Robertson N. (2009) Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: A systematic review. Mov Disord 24: 1636–1640.
65. Wild E. Tabrizi S. (2007 a) The differential diagnosis of chorea. Pract Neurol 7: 360–373.
66. Wild E. Tabrizi S. (2007 b) Huntington's disease phenocopy syndromes. Curr Opin Neurol 20: 681–687.